There are myriad targets that have been deemed undruggable and they "have rankled even the best-funded laboratories over the years," The Scientist says. However, some biotechs are game for taking those impossible targets on — and they appear to be seeing some success. The Scientist notes that one of those companies, Anchor Therapeutics, is working on targeting membrane receptors for Novartis and Ortho-McNeil-Janssen Pharmaceuticals.